Novartis Fights Enhanced Damages Bid After $178M Jury Loss

By Adam Lidgett · November 3, 2021, 6:15 PM EDT

Novartis says that it shouldn't have to pay enhanced damages after a jury hit the company with a $177.8 million verdict for selling a skin cancer drug that infringes two patents...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Plexxikon Inc. v. Novartis Pharmaceuticals Corporation

Case Number

Court

California Northern

Nature of Suit

Patent

Date Filed

August 03, 2017

Recent Articles By Adam

July 11, 2024
Senate Clears Patent Bill Aiming To Lower Drug Prices
June 07, 2024
DC Circ. Undoes Library Of Congress Win In Fair Use Fight
June 06, 2024
8th Circ. Affirms Cigna Noncompete Applies To CVS Hire
May 29, 2024
Greenberg Traurig Adds IP Atty From Eversheds Sutherland
May 20, 2024
Judge Tosses Acuitas' COVID Biotech IP Suit
April 30, 2024
FTC Continues To Target 'Junk' Drug Patents
April 10, 2024
Pharmacy Gets Eli Lilly's Mounjaro Suit Tossed
April 09, 2024
Endo Sues FDA Over Generic Adrenalin Approvals
March 25, 2024
Vidal Vacates Denials Of Challenges To Neo Wireless IP
March 21, 2024
Business Coalition Rebuffs Biden Plan To Seize Drug Patents